"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves Ibrutinib (Imbruvica) with Rituximab for treatment of Waldenstrom's macroglobulinemia (WM)

FDA Approves Ibrutinib (Imbruvica) with Rituximab for treatment of Waldenstrom's macroglobulinemia (WM)

21 Sep 2018 10:55 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved ibrutinib (Imbruvica; Pharmacyclics) plus rituximab (Rituxan) for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM). Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software